Hormone Therapy

Top Story

Postmenopausal estrogen use reduces risk for HCC

June 6, 2017

New data revealed an association between postmenopausal estrogen use and a reduced risk for hepatocellular carcinoma and increased overall survival time in women with HCC.

“In view of the notable male predominance of HCC, several investigators raised the question about the importance of sex hormones in HCC risk and prognosis. The liver expresses estrogen and androgen receptors, both of which may act as transcription factors and may regulate expression of several regulatory genes involved in several pathways including those associated with cell proliferation and immune response,” the researchers wrote. “This study demonstrates 50% reduction in HCC risk development among women who used [menopause hormone therapy].”

In the Journals Plus

Mortality increases with prior malignancy in children treated with GH

June 2, 2017
In children treated with growth hormone, those with a prior malignancy or an underlying serious medical condition unassociated with growth hormone deficiency had higher…
In the Journals PlusPerspective

Body composition reverts after testosterone therapy cessation in men with obesity

June 2, 2017
After cessation of a weight-loss program combined with testosterone therapy, men with obesity did not retain favorable changes in body composition, according to findings…
In the Journals Plus

Hormone therapy associated with hearing loss in postmenopausal women

May 31, 2017
In postmenopausal women, the use of oral hormone therapy is associated with a higher risk for hearing loss, with risk increasing with a longer duration of use, according…
CME CNE CPE CE

The Future of the Lipid Panel: An NLA Expert Discussion

This educational activity is supported by an educational grant from Quest Diagnostics, Inc.

Past-President of the National Lipid Association and Editor-in-Chief of the Journal of Clinical Lipidology, Dr. W…
More »
Video
Meeting News Coverage

Support for the transgender patient: What physicians need to know

June 2, 2014
More »
Featured
The Endocrine Society Annual Meeting

The Endocrine Society Annual Meeting

CME

Rapid Response from Austin: Expanding Options in Type 2 Diabetes Management

This activity is supported by educational grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.

Approximately 150 million people worldwide have diabetes mellitus and this number is expected to double by 2025…
More »
In the Journals

Postmenopausal estrogen use reduces risk for HCC

June 6, 2017
New data revealed an association between postmenopausal estrogen use and a reduced risk for hepatocellular carcinoma and increased overall survival…

In the Journals Plus

Mortality increases with prior malignancy in children treated with GH

June 2, 2017
In children treated with growth hormone, those with a prior malignancy or an underlying serious medical condition unassociated with growth hormone…

In the Journals PlusPerspective

Body composition reverts after testosterone therapy cessation in men with obesity

June 2, 2017
After cessation of a weight-loss program combined with testosterone therapy, men with obesity did not retain favorable changes in body composition…

In the Journals Plus

Hormone therapy associated with hearing loss in postmenopausal women

May 31, 2017
In postmenopausal women, the use of oral hormone therapy is associated with a higher risk for hearing loss, with risk increasing with a longer…

In the Journals Plus

Oral contraceptives associated with worsening lipid profile in PCOS

May 18, 2017
In women with polycystic ovary syndrome, the use of any oral contraceptive was associated with a rise in triglyceride and total cholesterol levels…

Perspective

USPSTF releases draft recommendation on menopausal hormone therapy

May 16, 2017
The U.S. Preventive Services Task Force has issued a draft recommendation against the use of combined estrogen and progestin for the prevention of…

FDA News

Long-term safety data needed for investigational estradiol vaginal softgel capsule

May 8, 2017
TherapeuticsMD recently received a Complete Response Letter from the FDA in reply to its New Drug Application for TX-004HR, an investigational…

Meeting News

Testosterone replacement therapy lowers mortality, CV risk in secondary hypogonadism

May 6, 2017
AUSTIN, Texas — Testosterone replacement therapy may lower the risk for myocardial infarction, stroke and all-cause mortality in men with…

Meeting News

Doping more prevalent among nonathletes vs. elite competitors

May 3, 2017
AUSTIN, Texas — Contrary to public perception, most androgen abusers are not elite athletes seeking to enhance performance, but instead are…

In the Journals Plus

Hormonal therapy fails to improve BMD in functional hypothalamic amenorrhea

May 2, 2017
Women with functional hypothalamic amenorrhea do not have significantly improved bone health with the use of hormonal therapy vs. placebo and calcium…

More Headlines »
Advertisement
Advertisement